PANOVISION: Feasibility and Safety of Hybrid IVUS-OCT System

Inclusion Criteria: * Age 18-75 years * Patients eligible for elective percutaneous coronary intervention * Understand and voluntarily sign the informed consent form Exclusion Criteria: The lesion-related exclusion criteria: * More than 1 stent was planned to deploy in culprit lesion * In-stent restenosis * Bifurcation lesion with proposed double stent implantation * The length of the reference vessel segment proximal or distal to the lesion was less than 5mm * The length of the implanted stent was larger than 33mm * The diameter of reference vessel was less than 2 mm or larger than 4 mm * Lesions were in left main or ostium of right coronary artery * The distance between either end of the lesion and the lateral branches larger than 2 mm in diameter was less than 5 mm * Angiography revealed thrombosis in culprit vessel * Severely calcified lesions or tortuous coronary arteries * Decreased blood flow (thrombolysis in myocardial infarction score ≤ 2) Patients-level exclusion criteria: * Breastfeeding or pregnant women, the subject (or his partner) who had a pregnancy plan during the trial or within 6 months after the end of the trial, and subject who did not agree to use contraception during the trial * Participants who had withdrawn from other clinical studies within 3 months or are participating in other clinical trials * Acute myocardial infarction occurred within one week prior to screening * Cardiac troponin I or cardiac troponin T levels exceed the upper limit of normal reference values within 72 hours of procedure and were of clinical significance * Renal insufficiency with creatinine \> 200μmol/L * Unsuitable for coronary artery bypass grafting (CABG) * Unsuitable for percutaneous coronary intervention; * Coronary spasm * Chronic total occlusion or subtotal occlusion * Severe hemodynamic disturbances or shock * History of CABG * Coagulation is abnormal and clinically significant * Severe heart failure (NYHA III, IV or Left ventricular ejection fraction \< 30%) * History of contrast allergy * Multi-vessel disease * Chemotherapy or planned chemotherapy * Investigators consider unsuitable for participants selected for this study